Despite recent leadership turmoil at the Justice Department, federal momentum to reschedule marijuana remains on a fast track with no expected delays to the administrative timeline. Industry experts and acting officials confirm that the transition to Schedule III is a priority and will be completed within 30 to 60 days.
Novus (stock symbol NDEV) introduces a prescription drug plan integrating a cannabis business model, which offers reimbursements to policyholders and cannabis-related ventures. As Medicare develops pilot programs, many carriers are expected to partner with Novus. This partnership offers a competitive edge by increasing policyholder retention and preventing policyholder churn between health plans.
- Supplemental Payout Certainty: As a supplemental carrier, Novus benefits are not dependent on a primary insurer’s approval. This allows for seamless reimbursement for medicinal cannabis and CBD, even when traditional carriers deny coverage.
- Elimination of Financial Barriers: The plan has zero deductibles and copays, removing the “out-of-pocket” friction that typically prevents patients from adhering to cannabinoid-based regimens.
- Broadened Enrollment: Benefits are non-contingent on pre-existing conditions, ensuring immediate network approval and a wider serviceable available market (SAM) than traditional clinical plans.
Medicare 2026: The CBD Pilot Catalyst
As of April 2026, the CMS Innovation Center has officially launched its pilot program, allowing Medicare organizations to offer hemp-derived CBD benefits (up to $500/year). This is a watershed moment for $NDEV:
- Validation of the Model: Medicare’s adoption of clinician-guided CBD access validates the very “cannabis-as-medicine” framework Novus has marketed for years.
- Network Expansion: With roughly 34 million Medicare Advantage beneficiaries now eligible for CBD discussions, Novus is positioned to offer its infrastructure as a turnkey “wrap-around” solution for providers participating in the CMS pilot.
Revenue Growth & Financial Trajectory ($NDEV)
Novus continues to demonstrate disciplined Year-over-Year (YoY) revenue expansion, driven by its dual-stream enrollment model:
- FY 2025 Total Revenue: $404,888 (a 9.82% increase over 2024).
- FY 2024 Total Revenue: $368,695 (a 7.83% increase over 2023).
- FY 2023 Total Revenue: $341,930 (an 11.84% increase over 2022).
- EBITDA (TTM): $195,236 (up 14.7% YoY), reflecting high-margin efficiency within their proprietary insurance tech stack.
- Shareholder Integrity: Zero insider selling in 36 months and a clean capital structure with no toxic convertible debt.
Federal Compliance: The Dual-Platform Strategy
To mitigate federal risk while maximizing market capture, $NDEV operates on two distinct, technologically separated platforms:
- The State-Legal THC Platform: Operates exclusively in jurisdictions with active medical marijuana programs. This platform handles provider-patient matching and preferred pricing at the dispensary level, ensuring all activity is intrastate-compliant.
- The Nationwide CBD/Health Platform: A federally compliant platform available in all 50 states. This covers hemp-derived CBD, telemedicine, dental, and vision.
By siloing these operations, Novus maintains its eligibility for traditional banking and merchant processing while remaining perfectly positioned to merge the platforms the moment federal Schedule III status is fully implemented.
Conclusion: For the investor, $NDEV represents a “regulatory arbitrage” play. The company has built the infrastructure for a future where cannabis is a standard pharmaceutical benefit, while its current revenue growth proves the model works even under the existing prohibition framework.
Investors can find many specific financial metrics, such as the company’s low or negative debt-to-equity ratio and its 2026 expansion strategy. What would you like to analyze next? See Further Due Diligence
About Novus
Further Research:
- Financial Filings: Click Here
- Quote: Click Here
- Investor’s Page: Click Here
Novus (NDEV), through its wholly owned subsidiary, WCIG Insurance Services, Inc., operates as a licensed health insurance carrier. The company provides proprietary health plans specifically for patients in states with legalized and regulated medical marijuana.
Revenue is generated through the stable, recurring collection of insurance premiums under the traditional insurance model. Crucially, Novus is not directly involved in the physical cannabis supply chain (cultivation, processing, distribution, or sale). This strategy allows Novus to operate within the regulated health insurance framework, bridging the gap between traditional insurance and the evolving medical marijuana landscape by offering compliant, specialized coverage.
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflect management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.
Investor Contact Information
855-228-7355
Email: info@getnovusnow.com
